Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

In light of the exploding popularity of GLP-1 medications like Ozempic and Wegovy, U.S. Anesthesia Partners, Inc. (USAP) is encouraging all patients taking GLP-1 receptor medication to consult with ...

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.